However, amifostine had no cytoprotective effect in transformed human tumour cells, suggesting that p53-dependent growth arrest is the basis for the protective effect of amifostine and that this pathway is abrogated in human tumours (Shen et al, 2001). Here, TP53 is linked to neoplasm.